Ocular Inflammation with Use of Oral Bisphosphonates
10.3341/jkos.2025.66.2.128
- Author:
Jee Hyun JEONG
1
;
Kyung Tae KANG
;
Yu Cheol KIM
Author Information
1. Department of Ophthalmology, Keimyung University School of Medicine, Daegu, Korea
- Publication Type:Case Report
- From:Journal of the Korean Ophthalmological Society
2025;66(2):128-131
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Purpose:To report a case of ocular inflammation after bisphosphonate use in a patient with osteoporosis.Case summary: A 54-year-old female presented to our clinic with eye pain and conjunctival and episcleral vessel injection in both eyes for 1 month. The patient was diagnosed with osteoporosis by the Department of Endocrinology 7 weeks ago and prescribed risedronate, a bisphosphonate. After using risedronate for 3 weeks, the patient developed generalized body pain, eye pain, and conjunctival injection. Slit lamp examination demonstrated conjunctival injection, whereas fundus examination did not reveal any cells in the anterior chamber or any other abnormal findings. Subsequently, risedronate was discontinued, which relieved the pain. At the 2-month follow-up visit in the outpatient department, the patient was asymptomatic, and there was no conjunctival injection.
Conclusions:Bisphosphonates can lead to ocular adverse effects, which should be considered in patients with osteoporosis presenting with nonspecific ocular inflammation.
